AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORTHOCELL LTD

0.800

-0.035-4.19%

Volume:113.27K

Turnover:90.37K

Market Cap:216.87M

PE:-15.34

High:0.820

Open:0.820

Low:0.790

Close:0.835

52wk High:1.600

52wk Low:0.700

Shares:271.09M

Float Shares:194.08M

Volume Ratio:0.40

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.052

EPS(LYR):-0.038

ROE:-41.06%

ROA:-20.97%

PB:5.27

PE(LYR):-20.85

Loading ...

Overview Company News Filings

Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says

MT Newswires Live

Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue

Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%

MT Newswires Live

BRIEF-Orthocell Says QTRLY A$3.2 Million Revenue Achieved

Orthocell Ltd - Qtrly a$3.2 Mln Revenue Achieved

THOMSON REUTERS

BUZZ-Australia's Orthocell set for best week since November 2024 on US DoD approval for key product

Stock Track | Orthocell Soars 7.84% Intraday on First Surgical Use of Nerve Repair Product in US Defense Hospital

Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed

MT Newswires Live

Orthocell Ltd-First Surgical Use of Remplir in US Department of Defense

THOMSON REUTERS

Orthocell wins approval to sell Remplir across US DoD, VA hospital networks

BRIEF-Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence Hospitals

Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks

MT Newswires Live

Orthocell Ltd - Receives Approval for Remplir in 51 Dod Hospitals and 170 Va Medical Centres

THOMSON REUTERS

Orthocell Says Proposed US Pharmaceutical Tariffs Not Expected to Apply to Remplir; Shares Up 4%

MT Newswires Live

BRIEF-Orthocell Says US Section 232 Tariffs Not Expected To Affect Remplir

Orthocell Ltd - US Section 232 Tariffs Not Expected to Affect Remplir

THOMSON REUTERS

Bell Potter just put a buy rating on this exciting small-cap ASX stock

Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target

MT Newswires Live

Orthocell's Remplir Device Aids 23 Surgeries in Ukraine

MT Newswires Live

Which exciting ASX All Ords stock is jumping on big news?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/OCC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OCC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":0.8,"timestamp":1787292720000,"preClose":0.835,"halted":0,"volume":113270,"delay":0,"changeRate":-0.041916167664670566,"nameEN":"ORTHOCELL LTD","floatShares":194076512,"shares":271090199,"eps":-0.052151,"marketStatus":"Market Closed","change":-0.035,"latestTime":"08-21 16:12:00 AEST","open":0.82,"high":0.82,"low":0.79,"amount":90372,"amplitude":0.035928,"askPrice":0.8,"askSize":684,"bidPrice":0.79,"bidSize":18829,"shortable":3,"etf":0,"ttmEps":-0.052151,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.835,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.4004072298551456,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"OCC.AU","preClose":0.835,"auctionPrice":0.8,"auctionVolume":824,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292445910}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":194076512,"roa":"-20.97%","roe":"-41.06%","lyrEps":-0.03837,"volumeRatio":0.4004072298551456,"shares":271090199,"dividePrice":0,"high":0.82,"amplitude":0.035928,"preClose":0.835,"low":0.79,"week52Low":0.7,"pbRate":"5.27","psRate":"23.24","week52High":1.6,"institutionHeld":0,"latestPrice":0.8,"committee":0.929893,"eps":-0.052151,"divideRate":0,"volume":113270,"delay":0,"ttmEps":-0.052151,"open":0.82,"prevYearClose":1.085,"prevWeekClose":0.77,"prevMonthClose":0.73,"prevQuarterClose":0.725,"fiveDayClose":0.77,"twentyDayClose":0.71,"sixtyDayClose":0.775},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[{"date":"2026-07-13","symbol":"OCC.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1783900800000,"name":null,"time":"","dateTimestamp":1783864800000,"actualEps":null},{"date":"2026-04-20","symbol":"OCC.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776643200000,"name":null,"time":"","dateTimestamp":1776607200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629771701","title":"Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2629771701","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629771701?lang=en_us&edition=fundamental","pubTime":"2026-04-21 12:43","pubTimestamp":1776746594,"startTime":"0","endTime":"0","summary":"Orthocell's  fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199733288","title":"Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1199733288","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199733288?lang=en_us&edition=fundamental","pubTime":"2026-04-20 12:28","pubTimestamp":1776659309,"startTime":"0","endTime":"0","summary":"Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.The biotech company reported revenue of AU$3.2 million for the March...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628528716","title":"Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628528716","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628528716?lang=en_us&edition=fundamental","pubTime":"2026-04-20 12:24","pubTimestamp":1776659078,"startTime":"0","endTime":"0","summary":"Orthocell (ASX:OCC) said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir, according to a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628797217","title":"BRIEF-Orthocell Says QTRLY A$3.2 Million Revenue Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2628797217","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628797217?lang=en_us&edition=fundamental","pubTime":"2026-04-20 09:33","pubTimestamp":1776648826,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says QTRLY A$3.2 Million Revenue AchievedApril 20 (Reuters) - Orthocell Ltd OCC.AX:QTRLY  A$3.2 MILLION REVENUE ACHIEVEDFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN411037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791580","title":"Orthocell Ltd - Qtrly  a$3.2 Mln Revenue Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628791580?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:05","pubTimestamp":1776639952,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nFWN411037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479221","title":"BUZZ-Australia's Orthocell set for best week since November 2024 on US DoD approval for key product","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479221","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628479221?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:40","pubTimestamp":1776397205,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell set for best week since November 2024 on US DoD approval for key product** Shares of Australian regenerative medicine co Orthocell OCC.AX rise 7.8% to A$1.1** Co says first surgical case using its nerve repair device Remplir completed in U.S Department of Defense  hospital network** Stock has risen 27.4% so far this week, set for best week since late November 2024** On Wednesday, stock gained 24.1% in its best day in more than a year on news that co has secured approval from U.S. DoD for use of Remplir** Stock down 6% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N41007H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137343106","title":"Stock Track | Orthocell Soars 7.84% Intraday on First Surgical Use of Nerve Repair Product in US Defense Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=1137343106","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137343106?lang=en_us&edition=fundamental","pubTime":"2026-04-17 08:02","pubTimestamp":1776384178,"startTime":"0","endTime":"0","summary":"ORTHOCELL LTD's stock soared 7.84% during intraday trading on Friday.The surge followed the company's announcement that the first surgical case using its nerve repair product, Remplir, has been...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628247750","title":"Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=2628247750","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628247750?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:31","pubTimestamp":1776382301,"startTime":"0","endTime":"0","summary":"Orthocell  said that a surgery at a military base hospital in Ohio within the US Department of Defense/Veterans Affairs hospital network was the first surgical case using its nerve repair product, Remplir, according to a Friday Australian bourse filing.The company said that this represented an important step in its US commercialization strategy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628247359","title":"Orthocell Ltd-First Surgical Use of Remplir in US Department of Defense","url":"https://stock-news.laohu8.com/highlight/detail?id=2628247359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628247359?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:01","pubTimestamp":1776380476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUE9SXV8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627263280","title":"Orthocell wins approval to sell Remplir across US DoD, VA hospital networks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627263280","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627263280?lang=en_us&edition=fundamental","pubTime":"2026-04-16 12:09","pubTimestamp":1776312543,"startTime":"0","endTime":"0","summary":"Orthocell secured approval to supply Remplir nerve repair device across US Department of Defense hospital network.Clearance opens access to 51 military hospitals, 170 Veterans Affairs medical centers.Orthocell plans to use distributor network covering 17 states to drive uptake in military, VA systems.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL6d8vxS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476498","title":"BRIEF-Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence Hospitals","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476498","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476498?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:28","pubTimestamp":1776216507,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence HospitalsApril 15 (Reuters) - Orthocell Ltd OCC.AX:ORTHOCELL LTD - RECEIVES APPROVAL FOR REMPLIR IN 51 DOD HOSPITALS AND 170 VA MEDICAL CENTRESSource text: ID:nASX9XYDV7Further company coverage: OCC.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478227","title":"Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478227","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478227?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:08","pubTimestamp":1776211731,"startTime":"0","endTime":"0","summary":"Orthocell  said it has secured approval for its Remplir nerve repair device to be used across the US Department of Defense and Veterans Affairs hospital networks, according to a Wednesday Australian bourse filing.The company said it will use its existing US distributor network to target military and VA surgeons operating within these hospital systems, which currently covers 17 states.The approval comes as Orthocell said it is seeing growing evidence of increasing commercialization and revenue momentum in the US market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420656","title":"Orthocell Ltd - Receives Approval for Remplir in 51 Dod Hospitals and 170 Va Medical Centres","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420656?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:01","pubTimestamp":1776207663,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625935449","title":"Orthocell Says Proposed US Pharmaceutical Tariffs Not Expected to Apply to Remplir; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935449","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625935449?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:37","pubTimestamp":1775612251,"startTime":"0","endTime":"0","summary":"Orthocell  does not expect its Remplir medical device to be subject to the US administration's proposed Section 232 tariffs under the Trade Expansion Act on pharmaceutical imports, as the device falls outside the tariff's scope, according to a Wednesday Australian bourse filing.The company is confident that its commercial rollout and growth strategy in the US will proceed without disruption or financial impact, the filing added.The company's shares rose around 4% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625962714","title":"BRIEF-Orthocell Says US Section 232 Tariffs Not Expected To Affect Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2625962714","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625962714?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:54","pubTimestamp":1775606056,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says US Section 232 Tariffs Not Expected To Affect RemplirApril 8 (Reuters) - Orthocell Ltd OCC.AX:US SECTION 232 TARIFFS NOT EXPECTED TO AFFECT REMPLIRFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q1EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625964217","title":"Orthocell Ltd - US Section 232 Tariffs Not Expected to Affect Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2625964217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625964217?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:06","pubTimestamp":1775603189,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q1EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620298772","title":"Bell Potter just put a buy rating on this exciting small-cap ASX stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2620298772","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620298772?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:52","pubTimestamp":1773870764,"startTime":"0","endTime":"0","summary":"Investors with a high tolerance for risk might want to check out the exciting small-cap ASX stock in this article. That's because the team at Bell Potter has just initiated coverage on it with a bullish view. Which small-cap ASX stock?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/bell-potter-just-put-a-buy-rating-on-this-exciting-small-cap-asx-stock/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/bell-potter-just-put-a-buy-rating-on-this-exciting-small-cap-asx-stock/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620237256","title":"Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237256?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:05","pubTimestamp":1773831933,"startTime":"0","endTime":"0","summary":"Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620340455","title":"Orthocell's Remplir Device Aids 23 Surgeries in Ukraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2620340455","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620340455?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:08","pubTimestamp":1773792484,"startTime":"0","endTime":"0","summary":"Orthocell  reported that its Remplir nerve repair device has been successfully used in 23 surgeries on injured Ukrainian soldiers, following a humanitarian delivery in April 2025, according to a Wednesday Australian bourse filing.The device was used in both primary and secondary nerve repairs, with surgeons reporting positive feedback on its portability, ease of use, and suitability for major trauma in defense settings, per the filing.The company plans to continue monitoring patient outcomes and collecting clinical data to support future engagement with defense organizations globally, the filing added.The company's shares rose 2% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620840106","title":"Which exciting ASX All Ords stock is jumping on big news?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620840106","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620840106?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:57","pubTimestamp":1773791866,"startTime":"0","endTime":"0","summary":"Orthocell Ltd  shares are catching the eye on Wednesday morning.In early trade, the ASX All Ords stock is up 5% to 82 cents.The company's shares are pushing higher today following the release of an announcement that highlights the real-world use of its Remplir device in a conflict setting.Remplir is a collagen nerve wrap used in the repair of peripheral nerve injuries. It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing.According to the release, the ASX All Ords stock's Remplir product has been used in 23 surgical procedures on injured soldiers in Ukraine.The company confirmed that the procedures followed a humanitarian delivery of the device to Ukraine in April 2025, with surgeons now successfully using Remplir in both primary and secondary nerve repair operations.In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/which-exciting-asx-all-ords-stock-is-jumping-on-big-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/which-exciting-asx-all-ords-stock-is-jumping-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}